Premium
A trial comparing nicardipine and cyclopenthiazide‐K in a group of general practice patients with mild to moderate hypertension
Author(s) -
MURRAY T. S.,
LANGAN J. J.,
COXHEAD P. F.
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb00328.x
Subject(s) - nicardipine , medicine , blood pressure , supine position , sphygmomanometer , sitting , isometric exercise , diastole , prehypertension , heart rate , anesthesia , randomized controlled trial , essential hypertension , cardiology , pathology
1 The study was a single‐blind, parallel comparison of the effects of nicardipine and cyclopenthiazide‐K given to patients with mild to moderate hypertension. Eight principal general practitioners admitted 91 patients. Forty‐four were randomised to cyclopenthiazide‐K and 47 to nicardipine. Blood pressure was measured using a random zero sphygmomanometer. 2 There were statistically significant decreases in systolic and diastolic blood pressures supine, standing and after hand grip isometric exercise in both groups of patients, relative to baseline. 3 Median blood pressure reduction over the 6 weeks of the study for sitting, standing and post‐submaximal exercise in the nicardipine group of patients was 171/105 to 149/88, 167/105 to 144/90 and 175/107 to 152/92 mm Hg respectively. In the cyclopenthiazide‐K group patients the changes were 172/105 to 151/94, 168/106 to 149/96 and 178/107 to 159/98 mm Hg respectively. The greater blood pressure reduction on nicardipine relative to cyclopenthiazide‐K was statistically significant at week 3 and 6 for supine, standing and post‐submaximal exercise diastolic blood pressure and at week 3 for post‐submaximal exercise systolic blood pressure. 4 Therapy was assessed by the investigating doctors as excellent, very good or good in 71% of nicardipine patients and in 55% of cyclopenthiazide‐K patients. 5 More patients reported side‐effects in the nicardipine group (25) than in the cyclopenthiazide‐K (16). This may have been related partly to their pre‐study therapy. There was some evidence for the acquisition of side‐effect tolerance in the nicardipine group. 6 In the nicardipine group there were no changes noted which could be suggested as long‐term cardiovascular risk factors, though some (reduced blood potassium, increased uric acid) were seen in the parallel cyclopenthiazide‐K group.